BOSTON, Aug. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2025, which ended June 29, 2024, are available on its Investor Relations website.
The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 8, 2024. The conference call and webcast can be accessed with the following information:
In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below.
Direct link to 1Q FY25 Earnings Release
A replay of the conference call and webcast will be available for one year beginning on August 8, 2024, at 11:00 a.m. ET using the conference call webcast link provided in this press release.
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Vice President-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Media Contact: | |
Josh Gitelson, Sr. Director-Global Communications | |
(781) 356-9776 | |
This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$78.77 |
| Daily Change: | -3.30 -4.02 |
| Daily Volume: | 493,017 |
| Market Cap: | US$3.960B |
August 15, 2024 July 30, 2024 June 18, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
